12:00 AM
 | 
Dec 04, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CI-1042: Phase II data; Phase III

ONXX published in Cancer Research results of a 37-patient U.S. Phase II trial of CI-1042 monotherapy. Among 24 evaluable patients (who completed at least 2 cycles of therapy), 4 of 19 who received a single daily intratumoral injection of the product for 5 days...

Read the full 199 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >